首页> 外文期刊>Journal of gastroenterology and hepatology >Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat.
【24h】

Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat.

机译:普伐他汀和苯扎贝特对大鼠胆汁脂质分泌和肝脏Abcg5和Abcg8表达的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Background and Aim: Multidrug resistance associated gene product 2 (Mdr2) is believed to have a significant role in biliary cholesterol and phospholipid secretions. Both pravastatin and bezafibrate resulted in Mdr2 induction, but increased cholesterol secretion was observed only in pravastatin treatment. To explore the mechanism, the hepatic expression of genes that are responsible for the metabolism of the lipids was studied. Methods: Rats were divided into three experimental groups: (i) the control group; (ii) the bezafibrate group, which was fed a diet containing 0.45% bezafibrate for 5 days; and (iii) the pravastatin group, which was fed a diet containing 0.1% pravastatin for 5 days. Serum, hepatic and biliary lipids were measured by colorimetric assays and hepatic mRNA related to lipid metabolism was studied by reverse transcription-polymerase chain reaction (RT-PCR). Results: In the bezafibrate group biliary phospholipid secretion was increased although cholesterol secretion was not increased. In the pravastatin group, biliary cholesterol and phospholipid secretions were significantly increased. The biliary cholesterol/phospholipid ratio was decreased in the bezafibrate group, but the ratio did not change in the pravastatin group. Hepatic Mdr2, Abcg5 and Abcg8 mRNA expression was remarkably increased in the pravastatin group in comparison with the control group (184%, 264% and 247% of control value, respectively). In the bezafibrate group the hepatic gene expression of Mdr2 was increased (157% of control value), but there were no significant changes in hepatic Abcg5 and Abcg8 mRNA expression compared with the control group. Conclusions: Compared with Mdr2, Abcg5 and Abcg8 seem to be more essential transporters for biliary secretion of cholesterol. Pravastatin upregulated Abcg5/Abcg8 while bezafibrate did not, which appears to explain the different effects of these compounds on biliary lipid secretion. Copyright 2004 Blackwell Publishing Asia Pty Ltd
机译:摘要背景与目的:多重耐药相关基因产物2(Mdr2)被认为在胆汁胆固醇和磷脂分泌中具有重要作用。普伐他汀和苯扎贝特均引起Mdr2诱导,但仅在普伐他汀治疗中观察到胆固醇分泌增加。为了探索该机制,研究了负责脂质代谢的基因的肝表达。方法:将大鼠分为三个实验组:(i)对照组; (ii)苯扎贝特组,饲喂含0.45%苯扎贝特的饮食5天; (iii)普伐他汀组,接受含0.1%普伐他汀的饮食5天。通过比色测定法测定血清,肝和胆汁脂质,并通过逆转录-聚合酶链反应(RT-PCR)研究与脂质代谢相关的肝mRNA。结果:苯扎贝特组胆汁磷脂分泌增加,尽管胆固醇分泌没有增加。普伐他汀组的胆汁胆固醇和磷脂分泌显着增加。苯扎贝特组胆汁胆固醇/磷脂比例降低,普伐他汀组胆汁胆固醇/磷脂比例未改变。与对照组相比,普伐他汀组肝Mdr2,Abcg5和Abcg8 mRNA的表达显着增加(分别为对照组的184%,264%和247%)。在苯扎贝特组中,Mdr2的肝基因表达增加(控制值的157%),但与对照组相比,肝Abcg5和Abcg8 mRNA的表达无明显变化。结论:与Mdr2相比,Abcg5和Abcg8似乎是胆汁中胆固醇分泌的重要转运蛋白。普伐他汀上调Abcg5 / Abcg8,但苯扎贝特不上调,这似乎可以解释这些化合物对胆脂分泌的不同作用。版权所有2004 Blackwell Publishing Asia Pty Ltd

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号